Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Argenx Se (ARGX)
NASDAQ:ARGX
Holding ARGX?
Track your performance easily
ARGX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$327.73 - $611.22
Previous Close$605.92
Volume363.52K
Average Volume (3M)267.52K
Market Cap
$36.64B
Enterprise Value$34.61B
Total Cash (Recent Filing)$2.05B
Total Debt (Recent Filing)$20.00M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Feb 27, 2025EPS Estimate
$1.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.50
Shares Outstanding59,194,488
10 Day Avg. Volume323,041
30 Day Avg. Volume267,524
Standard Deviation0.12
R-Squared0.08
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)8.55
Price to Sales (P/S)83.60
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue162.37
Enterprise Value/Gross Profit31.23
Enterprise Value/Ebitda-75.90
Forecast
1Y Price Target
$665.45Price Target Upside9.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
Argenx Se News
Bulls Say, Bears Say
Bulls Say
Business StrategyOptimism around the potential for self-administration could be a significant growth driver for Vyvgart, enhancing its market uptake and competitive positioning.
Clinical TrialsEfgartigimod advances in all three subtypes of myositis based on positive Phase 2 results, showing statistically significant improvements in the mean total improvement score.
Market PotentialEfgartigimod could potentially be the first targeted treatment for myositis, addressing a significant unmet need and offering a first mover advantage relative to cell therapies.
Bears Say
Competitive PressureThere are several bigger questions surrounding Argenx, such as the impact of upcoming data from competitors like Roche, which need to be closely monitored.
Safety ConcernsSafety concerns include numerical albumin drops and LDL increases with 15 mg/kg Q2W nipocalimab, which have not been seen with Vyvgart.
Trial Design FlawsCurrent Ph.2 trial for BP has design flaws and ARGX is analyzing Part B data to decide on the next steps.
---
Ownership Overview
―
Insiders
22.86% Mutual Funds
24.94% Other Institutional Investors
50.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARGX FAQ
What was Argenx Se’s price range in the past 12 months?
Argenx Se lowest stock price was $327.73 and its highest was $611.22 in the past 12 months.
What is Argenx Se’s market cap?
Currently, no data Available
When is Argenx Se’s upcoming earnings report date?
Argenx Se’s upcoming earnings report date is Feb 27, 2025 which is in 94 days.
How were Argenx Se’s earnings last quarter?
Argenx Se released its earnings results on Oct 31, 2024. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $0.147 by $1.243.
Is Argenx Se overvalued?
According to Wall Street analysts Argenx Se’s price is currently Undervalued.
Does Argenx Se pay dividends?
Argenx Se does not currently pay dividends.
What is Argenx Se’s EPS estimate?
Argenx Se’s EPS estimate is $1.31.
How many shares outstanding does Argenx Se have?
Argenx Se has 60,367,650 shares outstanding.
What happened to Argenx Se’s price movement after its last earnings report?
Argenx Se reported an EPS of $1.39 in its last earnings report, beating expectations of $0.147. Following the earnings report the stock price went up 6.27%.
Which hedge fund is a major shareholder of Argenx Se?
Among the largest hedge funds holding Argenx Se’s share is Perceptive Advisors LLC. It holds Argenx Se’s shares valued at 64M.
---
Argenx Se Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$665.45 (9.82% Upside)
$665.45 (9.82% Upside)
Blogger Sentiment
Bullish
ARGX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 17.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.15%
12-Months-Change
Fundamentals
Return on Equity
-5.75%
Trailing 12-Months
Asset Growth
50.18%
Trailing 12-Months
Company Description
Argenx Se
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
---
ARGX Earnings Call
Q3 2024
0:00 / 0:00
---
ARGX Stock 12 Month Forecast
Average Price Target
$665.45
▲(9.82% Upside)
Technical Analysis
Best Analysts Covering ARGX
1 Year
1 Year Success Rate
18/19 ratings generated profit
1 Year Average Return
+27.20%
assigned a buy rating 24 days ago
Copying Allison Bratzel's trades and holding each position for 1 Year would result in 94.74% of your transactions generating a profit, with an average return of +27.20% per trade.
---